1 McGill Nutrition and Food Science Centre, Royal Victoria Hospital, Montreal, Quebec, Canada H3A 1A1; 2 Department of Internal Medicine and Institute of Gerontology, University of Michigan and Veterans Affairs Medical Center, Ann Arbor, Michigan 48109; and 3 Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada M5S 1A8
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The glucoregulatory response to intense
exercise [IE, >80% maximum O2 uptake
(O2 max)]
comprises a marked increment in glucose production (Ra) and
a lesser increment in glucose uptake (Rd), resulting in
hyperglycemia. The Ra correlates with plasma catecholamines but not with the glucagon-to-insulin (IRG/IRI) ratio. If epinephrine (Epi) infusion during moderate exercise were able to markedly stimulate
Ra, this would support an important role for the
catecholamines' response in IE. Seven fit male subjects (26 ± 2 yr,
body mass index 23 ± 0.5 kg/m2,
O2 max 65 ± 5 ml · kg
1 · min
1)
underwent 40 min of postabsorptive cycle ergometer exercise (145 ± 14 W) once without [control (CON)] and once with Epi infusion [EPI (0.1 µg · kg
1 · min
1)]
from 30 to 40 min. Epi levels reached 9.4 ± 0.8 nM (20× rest, 10× CON). Ra increased ~70% to 3.75 ± 0.53 in
CON but to 8.57 ± 0.58 mg · kg
1 · min
1
in EPI (P < 0.001). Increments in Ra and Epi
correlated (r2 = 0.923, P
0.01). In EPI,
peak Rd (5.55 ± 0.54 vs. 3.38 ± 0.46 mg · kg
1 · min
1,
P = 0.006) and glucose metabolic clearance rate (MCR, P = 0.018) were higher. The Ra-to-Rd
imbalance in EPI caused hyperglycemia (7.12 ± 0.22 vs. 5.59 ± 0.22 mM, P = 0.001) until minute 60 of recovery. A
small and late IRG/IRI increase (P = 0.015 vs. CON) could not
account for the Ra increase. Norepinephrine (~4×
increase at peak) did not differ between EPI and CON. Thus Epi infusion during moderate exercise led to increments in Ra and
Rd and caused rises of plasma glucose, lactate, and
respiratory exchange ratio in fit individuals, supporting a regulatory
role for Epi in IE. Epi's effects on Rd and MCR during
exercise may differ from its effects at rest.
glucose turnover; catecholamines; insulin; glucagon
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
METABOLIC RESPONSES TO EXERCISE differ according to its
intensity and duration. Glucoregulation at low and moderate intensity is primarily mediated by an increase in the portal venous
glucagon-to-insulin ratio [IRG/IRI (36)], which stimulates
hepatic glucose output (endogenous Ra), thereby maintaining
euglycemia largely through a feedback mechanism (2, 17, 18, 45) that
matches the increment in Ra to the increased requirements.
However, in intense exercise [IE, 80% of maximum
O2 uptake
(
O2 max)]
glucoregulation differs. A rapid and massive increase (
8-fold) in
Ra and a rise in glycemia occur, but plasma insulin (IRI)
either remains constant or decreases slightly, and glucagon (IRG)
increases less than twofold (26, 37, 38, 39). It seems unlikely that
these small changes, even insofar as they reflect portal vein
concentrations, would be sufficient for IRG/IRI to play the leading
glucoregulatory role in IE. Furthermore, the Ra response
was unaffected in islet cell clamp studies using somatostatin and
exogenous hormone infusions, in which peripheral IRG-to-IRI ratios
(representative of portal levels) were kept unchanged or were even
decreased (37).
A "feedforward" mechanism for the regulation of hepatic glucose output during IE has been proposed (20, 45), which conceptually may be better suited to maintaining homeostasis during such extreme physiological conditions. We (24, 26, 37-39) and others (4, 20) have proposed that the rapid and marked catecholamine response of IE could be such a mechanism. Plasma norepinephrine (NE) and epinephrine (Epi) concentrations can both increase ~15-fold, and we have repeatedly demonstrated highly significant correlations of both with Ra during IE (24, 26, 37-39). We recently found that the patterns of plasma catecholamines, Ra, and their correlations also persist in subjects infused with glucose (24) or studied in the postprandial state (27). These are situations in which endogenous Ra suppression from hyperinsulinemia must be overcome, the latter being the situation under which most IE is actually performed. These responses differ from those at lower-intensity exercise in which attenuation or complete prevention of the endogenous Ra increment occurs with exogenous glucose infusion (2, 17, 18, 41, 45).
Catecholamine infusions stimulate Ra in both dogs (8, 12,
40) and humans (5, 10, 15, 19, 30-34). Most of these studies
involved only Epi and were done at rest. Although some (5, 30) produced
Epi levels comparable to those of IE, the 1.5- to 2.5-fold increments
in Ra were considerably smaller. The increment in
Ra from Epi was much greater than that from NE infusion in
both humans (32) and dogs (8). This is consistent with hepatic
denervation and adrenodemedullation studies in animals that have
suggested the greater importance of Epi than NE in stimulating Ra (23, 44). One study of Epi infusion during exercise was performed on celiac ganglion-blocked and islet cell-clamped human subjects exercising at 74%
O2 max. Epi was doubled
by the infusion to concentrations typical of IE and was associated with
a further increment in Ra over that of the exercise alone
(19). A recent study (15) with Epi infusion during 40%
O2 max exercise
suggested that Epi contributes to but does not fully account for the
Ra increment of IE. Glucose disposal (Rd),
however, is ordinarily inhibited by Epi (35). Epi infusions at rest in
both dogs (12) and humans (5, 30-32) caused little change in
Rd, but because glucose concentrations increased, this
resulted in a 20-40% decline in metabolic clearance rates
(MCR). Studies of Epi infusion during exercise in humans (15, 16,
19) have yielded differing Rd results.
Therefore, to further test the hypothesis that catecholamines are the
primary mediators of the Ra response to IE by defining the
metabolic effects of Epi during exercise, we studied fit lean young
males undergoing 40 min of postabsorptive exercise at 50% O2 max with and without
infusion of 0.1 µg · kg
1 · min
1
of epinephrine from 30 to 40 min. Results of these studies have been
presented in part in abstract form (25).
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Participants were seven lean weight-stable fit men aged 19-31 yr
(Table 1). All engaged in regular activity
such as running, cycling, soccer, and/or rowing, combined in some with
resistance training. Screening before the study included medical
history, physical examination, hemogram, blood biochemistry,
urinalysis, hepatitis B and HIV serology, electrocardiogram, and chest
roentgenogram. Subjects were informed of the purpose of the study and
of the possible risks, and they gave signed consent as prescribed by the institutional human ethics committee.
|
O2 max was determined
at a preliminary visit with breath-by-breath analysis during an
incremental workload test (20 W/min) on an electrically braked cycle
ergometer (Collins Metabolic Cart, Collins, Braintree, MA). Oxygen
uptake (
O2,
STPD), carbon dioxide output
(
CO2, STPD),
ventilation (
E, l/min,
BTPS), respiratory exchange ratio (RER), and heart rate
were measured. The studies with glucose turnover measurements began
between 0800 and 0900 with subjects in the 12-h overnight fasting state
without having undergone any significant exercise in the preceding 24 h. Twenty-gauge intravenous cannulas were placed in both arms. A
priming bolus of 22 µCi of HPLC-purified
[3-3H]glucose tracer (Du Pont-NEN, Billerica,
MA) was followed by a constant infusion of 0.22 µCi/min in 0.9%
saline, except where otherwise specified. Blood was sampled at six
10-min intervals before time 0 (beginning of exercise) to
assure a steady state of plasma [3H]glucose
specific activity (SA). The subjects then cycled for 40 min at
50%
O2 max,
followed by a 120-min recovery period. The exercise intensity level was
achieved by using 45% of the maximum workload reached during the
incremental workload test and by making minor adjustments so that a
steady state at 50%
O2 max was reached
early during the study. Experiments with and without Epi infusion (EPI
vs. CON) were separated by
2 wk, and the subjects were unaware of
which infusate was being received. In the EPI experiment, epinephrine
HCl (Abbott Laboratories, Saint-Laurent, QC) in isotonic saline and 1 mg/ml of ascorbic acid (as antioxidant, Sabex, Boucherville, QC) was
infused at 0.1 µg · kg
1 · min
1
from 30 to 40 min of exercise. In the CON experiment, only ascorbic acid in saline was infused.
Glucose SA was maintained by increasing the tracer infusion threefold during the Epi infusion and then returning it to the preexercise rate at minute 40. The goal was to introduce labeled glucose into the circulation at a rate proportional to endogenous Ra, thereby attenuating changes in [3H]glucose SA to <25% during the rapid changes in glucose kinetics, as in previous experiments (24, 26, 27, 37-39). This assures the validity of glucose turnover calculations (11), even if there may be changes in pool fraction during this time. Blood samples were drawn at intervals shown by the data in the figures.
Samples for glucose turnover measurements were placed into tubes
containing heparin and sodium fluoride and were processed as previously
described (24). Heparinized plasma was collected with aprotinin
(Trasylol, 10,000 kallikrein inhibitor U/ml, FBA, New York, NY) for
subsequent IRI and IRG assays. For catecholamine measurements, blood
was added to EGTA and reduced glutathione-containing tubes, and the
plasma was frozen at 70°C until assay. One aliquot of whole
blood was immediately deproteinized in an equal volume of cold 10%
(wt/vol) perchloric acid, kept on ice until centrifuged at 4°C, and
then frozen at
20°C for later lactate and pyruvate assays.
Glucose was measured by the glucose oxidase method with a Glucose Analyzer II (Beckman, Fullerton, CA). Blood lactate and pyruvate were measured by enzymatic microfluorometric methods, and IRI and IRG were measured by RIA, as previously detailed (37). Assays that were performed on aprotinin-containing plasma were corrected for the plasma dilution introduced. Plasma NE and Epi were measured using a radioenzymatic technique (sensitivity <50 pmol/l) (9). The intra-and interassay coefficients of variation for all assays were <10%; for the enzymatic assays they were <5%. Ra and Rd were calculated from the variable isotope infusion protocols according to the one-compartment model (29) using a glucose distribution space of 25% body wt and with a pool fraction of 0.65 representing the part in which the rapid changes of glucose and SA occur. Data were systematically smoothed by the OOPSEG (optimized optimal segments) program, which continually reconstructs and retests the curve until the residual differences between it and the data points are considered random and thus should represent measurement error (3). Glucose MCR was calculated by dividing Rd by the plasma glucose concentration.
Baseline characteristics were analyzed by one-way ANOVA. Plasma glucose, SA, glucose turnover, MCR, lactate, pyruvate, catecholamine, and hormone results were analyzed by ANOVA for repeated measures. Interstudy differences found to be significant (P < 0.05) were subsequently analyzed by the Student-Newman-Keuls (SNK) t-test. Paired Student's t-tests were used for analysis of some differences within the same study over time. Linear correlations were calculated with the Pearson correlation coefficient. Individual correlation coefficients were calculated by using all data points for each individual at which catecholamines and Ra were measured in the specified intervals. This correlation coefficient was then treated as a continuous variable on which means and standard error were calculated, and intergroup differences were assessed using one-way ANOVA, ANOVA for repeated measures, and the SNK tests. The SAS-STAT software package (SAS Institute, Cary, CA), SPSS-Windows Release 6.0 software package (SPSS, Chicago, IL), Microsoft Excel 5.0 Analysis ToolPak (GreyMatter International, Cambridge, MA), and Primer Biostats (McGraw-Hill, New York, NY) were used. Data are presented as means ± SE.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No untoward effects were experienced, and subjects were not able to
identify the CON vs. the EPI studies. Anthropometric measures, O2 max, and workload
data are presented in Table 1. Percent
O2 max reached during
the two studies was not significantly different (EPI, 51.9 ± 0.6%;
CON, 52.0 ± 0.4%). RER (Fig. 1) was not
different between studies at baseline or during the first 30 min of
exercise, during which it rose rapidly by minute 6 to ~0.90
and then declined slightly (P < 0.05) in both studies. It rose rapidly during the Epi infusion to a maximum of 0.96 (P = 0.010 vs. CON). Heart rate increased with Epi infusion (P < 0.001, ANOVA) to higher than that in CON at minutes 35 and
40 (P
0.05, paired t-test) although not by
repeated-measures ANOVA. Neither systolic nor diastolic blood pressure
differed between studies at any time.
|
Plasma glucose concentrations (Fig. 2) were
not different between studies at baseline, increasing slightly with
exercise in both studies (maximum 7.0% in EPI, 6.3% in CON; P = 0.003 for both). It rose abruptly (19.9%) from minute 30 to
minute 40 in EPI (P < 0.001) to 6.15 ± 0.17 mM, becoming higher than CON (5.22 ± 0.25 mM) from 38 to 40 min
(P = 0.038). Peak glycemia was reached at minute 5 of
recovery (7.12 ± 0.22 in EPI, 5.59 ± 0.22 mM in CON), and it
remained higher in EPI (P = 0.001) for 60 min. In CON, no
significant change occurred during recovery.
|
Ra (Fig. 3A) did not
differ between studies at baseline or during the progressive 70% rise
during the first 30 min of exercise. Although Ra remained
at this level in CON (3.75 ± 0.53 mg · kg1 · min
1
at minute 28), it increased markedly to >8
mg · kg
1 · min
1
within 2 min of the Epi infusion, reaching a maximum of 8.57 ± 0.58 mg · kg
1 · min
1
at minute 38. It was higher than in CON during infusion and for the first 10 min of recovery (P < 0.001). Ra fell
to baseline values at minute 20 of recovery in both. Although
it remained constant thereafter in CON, it continued to decline in EPI
to a nadir of 1.32 ± 0.12 mg · kg
1 · min
1
at minute 50 of recovery, remaining less than in CON from
minute 30 to minute 90 of recovery (P = 0.029).
|
Neither glucose Rd (Fig. 3B) nor MCR (Fig.
3C) differed between studies at baseline or during the first 30 min of exercise. Rd gradually rose by ~70% and MCR by
~80%. Values plateaued in CON, but in EPI, both increased markedly
within 2 min of starting the infusion to a maximum Rd of
5.55 ± 0.54 mg · kg1 · min
1
at minute 32 (vs. 3.38 ± 0.46 mg · kg
1 · min
1
at minute 30 in CON), and a maximum MCR of 6.16 ± 0.64 ml · kg
1 · min
1
at minute 32 (vs. 4.08 ± 0.89 ml · kg
1 · min
1
at minute 28 in CON). Both Rd (P = 0.006)
and MCR (P = 0.018) were higher in EPI throughout the infusion.
Both fell abruptly early in recovery and then remained at slightly
higher than baseline levels for the first hour of recovery. Neither
differed significantly from CON during the recovery period.
IRI (Fig. 4A) was not different
between studies at baseline and remained constant throughout from
minutes 0 to 30 and from minutes 30 to
40 of exercise. Although the early-recovery rise in IRI was
much greater in EPI (70%, P = 0.003 vs. 11%, P = 0.048), corresponding to the greater hyperglycemia at this time, the
differences did not reach significance. IRG (Fig. 4B) was not
different at baseline and remained constant during the first 30 min of
exercise in both studies and from minutes 30 to 40 in
CON. During the Epi infusion, it rose progressively by 29% (P < 0.001). The difference was significant (P = 0.038) at
minute 40 by paired t-test. It did not differ between
studies during recovery. The IRG-to-IRI molar ratio (Fig. 4C)
also did not differ between studies at baseline and remained constant
during the first 30 min of exercise. It increased 40% (P < 0.001) during the Epi infusion, becoming higher than CON at minute
40 (P = 0.015, paired t-test). It then fell in
early recovery in EPI (P = 0.001). Although by paired
t-tests the ratio was significantly higher in CON (P < 0.03) from minutes 10 to 60 of recovery (the period
of hyperglycemia in EPI), it was not different by repeated-measures
ANOVA (P = 0.089).
|
The plasma Epi (Fig. 5A) did not
differ between studies at baseline (0.45 ± 0.05 in EPI, 0.42 ± 0.06 nM in CON) or during the first 30 min of exercise, during which it
gradually doubled. Although in CON Epi did not change from minutes
30 to 40 of exercise (0.99 ± 0.10 nM at minute
35), in EPI it rose immediately and markedly to 9.15 ± 0.98 nM at
minute 35 and 9.43 ± 0.75 nM at minute 40 (P < 0.001 vs. CON). Levels fell abruptly after the simultaneous
termination of exercise and discontinuation of the infusion in EPI,
such that baseline values were approached at minute 5 and
reached at minute 20 of recovery. In CON, baseline values were
reached at minute 5. EPI subjects' concentrations were thus
higher for the first 20 min of recovery (P = 0.004). The
changes in Epi (between the two studies for each subject) correlated
significantly with the changes in Ra in all seven subjects when taken individually (mean r2 = 0.923; range,
0.834-0.967; P 0.01 for all) from minute 30 of
exercise to minute 20 of recovery (corresponding to the time when Epi levels were significantly higher in the EPI studies). Plasma
NE (Fig. 5B) did not differ between studies at baseline during
exercise (gradually increasing about fourfold) or during its return to
baseline during recovery.
|
Neither blood lactate (Fig. 6A) nor
pyruvate (Fig. 6B) was different between groups at baseline;
both rose during the first 10 min of exercise to a plateau, not
differing between studies during the first 30 min. However, both
lactate (P = 0.018 vs. CON) and pyruvate (P = 0.042 vs.
CON) then underwent another rise during the Epi infusion, peaking at
minute 40 and remaining higher (P = 0.014 for lactate,
P = 0.005 for pyruvate) than in CON throughout recovery.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
A feedforward mechanism for the regulation of hepatic glucose output
during IE has been proposed (20, 45). Previous results from our group
have been consistent, with plasma catecholamines being the primary
mediators of this response (24, 26, 27, 37-39); however, this
hypothesis remains controversial (6, 7, 15, 16, 19, 21). The principal
aim of this study was to define the potential role of epinephrine in
stimulating hepatic glucose output during IE by attempting to
"convert" the Ra response of moderately intense
exercise to that of IE with an infusion to reproduce IE epinephrine
levels. The results confirm that epinephrine is able to produce
appropriate metabolic responses when present in elevated circulating
concentrations. After the typical modest glucoregulatory and
catecholamine responses to 50%
O2 max exercise, the
infused subjects showed a marked and rapid Ra increment in association with the marked increment in plasma epinephrine.
Furthermore, other responses typical of IE were generated, including
rising glycemia due to a lesser increment of Rd than
Ra, elevated RER, and rises in lactate and pyruvate levels.
The early-recovery hyperglycemia and hyperinsulinemia typical of IE
also occurred.
Quantitative analysis and interpretation of the responses require
reference to those of exercise at >80%
O2 max. The
plasma epinephrine levels achieved during this study (~9 nM) were
higher than we have observed at exhaustion (~4-7 nM) with
87-100%
O2 max exercise (24, 26, 37, 39). However, comparable levels were reported by
others (8.73 nM) during short maximal bursts (2 min at 110%
O2 max) (20), and we
observed higher levels during
-adrenergic blockade (38). Endogenous
levels increased by only ~0.5 nM during the first 30 min of exercise,
as expected for exercise of this intensity (22); therefore, considering only the increment induced by the infusion would still result in levels
generally somewhat above the range of IE. We propose that our results
are still physiologically relevant. A much lower epinephrine infusion
yielding levels of only ~2 nM was shown to account for 32% of the
rise in Ra from 40 to 80%
O2 max (with an
Ra increment only 3.7-fold baseline), implying an even
greater contribution at higher exercise intensities (15). On the other hand, Ra peaked at ~12-14
mg · kg
1 · min
1
at 87%
O2 max,
and 16.7 mg · kg
1 · min
1
at 90-100%
O2 max
(39), compared with ~8.5
mg · kg
1 · min
1
at minute 10 of epinephrine infusion in the present study,
despite the high epinephrine levels. These peak values occurred at
exhaustion at minute 14-15 of IE, whereas at minute
10 of exercise, Ra reached 8-10
mg · kg
1 · min
1.
It can be argued that the exercise duration factor is unlikely to have
accounted for the lower peak in EPI, because Ra reached this level within 2 min of commencing the infusion and showed little
tendency to rise further. Another potential explanation of the lower
Ra relates to partial depletion of hepatic glycogen stores
during the initial 30 min of exercise. This effect would likely be
minor, because only ~10% of the 70-90 g of postabsorptive hepatic glycogen content (35) would have been consumed.
Therefore, although epinephrine caused a marked increment in Ra, suggesting that it is a major contributor, there are likely to be additional contributors to the response, as was suggested recently (15). Norepinephrine is a likely candidate (7, 15, 24, 26, 27, 37-39); studies of norepinephrine infusion in dogs (8) and humans (32) showed stimulation of Ra, although less than from equivalent infusion rates of epinephrine. These findings define only the potential potency of circulating norepinephrine, because peripheral infusions would not match the probable local concentrations and/or effects due to release at intrahepatic sympathetic nerve terminals. Another possibility is that combined epinephrine and norepinephrine effects are equal to or greater than the sum of the two individual effects. Yet another is that epinephrine (or total catecholamines) require(s) a yet-unidentified exercise intensity-dependent neuromuscular, mechanical, humoral, and/or blood flow setting for full effect. This latter hypothesis could explain why other studies of similar rates of epinephrine infusion (5, 30-34) at rest resulted in much lower Ra increments than we and others (19) found during exercise. In addition, timing of sampling for glucose kinetics may also have been a factor, because several of the resting studies first calculated Ra at 15 min or later after initiation of infusion. The effect of epinephrine on liver glycogenolysis is rapid and transient [(35, 40), being attenuated by counterregulatory responses that would be unlikely to occur to any significant degree during exercise], so a greater early response could have been missed. A third factor is likely to be a contribution by the increase in the IRG-to-IRI molar ratio.
Although it is known that epinephrine can stimulate glucagon release, its effects on glucose turnover are independent of this effect (12). The 40% rise in IRG/IRI induced by the epinephrine infusion may be an underestimate of the portal venous changes in this ratio (42); nonetheless, the magnitude of this change is still too small to account for such a large Ra response (14, 43). In addition, it occurred with a time course inappropriate to explain the Ra response, as we have also found in other experiments without catecholamine infusions (26, 27). Although IRG/IRI increased progressively (Fig. 4C), the Ra response was a nearly instantaneous rise to nearly maximum followed by plateau (Fig. 3A). The analysis of time courses provides strong additional support for epinephrine as a primary mediator, because it too followed such a time course (Fig. 5A).This is consistent with our previous IE studies, in which both Ra and catecholamines followed a rapid progressive parallel increase. Changes in peripheral IRG/IRI, on the other hand, did not follow such a pattern, reaching statistically significant increases only at exhaustion (26, 27). Because proportionally more insulin than glucagon is taken up by the liver at rest, it is difficult to predict portal levels from peripheral plasma concentrations during exercise. The most compelling argument for the magnitude of portal IRG/IRI changes being minor contributors to Ra in IE is that, during our islet cell clamp study, their portal levels were likely equal to peripheral levels, and either they did not change or they decreased, yet the rapid and large Ra response was unaffected (37).
A number of experimental findings have been interpreted as inconsistent
with the hypothesis of catecholamine mediation of Ra in IE
(6, 7, 15, 16, 19, 21). Many of these may be explained by the absolute
intensity of the exercise being lower than that which we hypothesize as
the threshold above which the catecholamines become key regulators. For
example, in the celiac ganglion blockade study (19), there was no
attenuation of Ra, despite the lowering of plasma
epinephrine and norepinephrine levels in those not infused with
epinephrine. However, the subjects were exercising at <75%
O2 max,
Ra increased only threefold, and lactate levels peaked at
only 5 mM, demonstrating a less-than-intense level of exercise in this
experiment. Another study (21) showed no significant attenuation of
Ra in subjects who had undergone liver transplantation,
exercising at 82%
O2 max. However, the absolute intensity was quite low [only 68 vs. 123 W in their
controls, 145 W in the current study, and ~260 W in our subjects
exercising at 87%
O2 max (27)].
This was reflected in an Ra increment of only 2.1-fold
matched by Rd, resulting in constant plasma glucose levels;
all these are markers of the metabolic response to low-to-moderate intensity exercise. A study of untrained subjects cycling for 30 min at
80%
O2 max (6) showed
no significant lesser increment in Ra during islet cell
clamp, and because epinephrine rose only fourfold in the clamped
subjects, the latter was felt not to be a significant factor in the
preserved response. However, the duration of exercise, constant
glycemia, matched Ra and Rd increments of only
3- to 3.5-fold, and the lesser epinephrine responses in both groups
point to a lower absolute intensity of exercise than in our
experiments. It does, however, suggest that our results may not be
applicable to untrained individuals except possibly at the highest of
exercise intensities. Another study showed a lack of attenuation of
Ra in dogs during "heavy" exercise with portal vein
infusion of phentolamine and propranolol (7). Beyond potential species-related differences in the metabolic response to exercise, in
that study, Ra increased only ~2.5-fold, plasma
catecholamines increased only 2.5- to 3-fold and lactate <2.5-fold.
Two of the cited references (15, 16) present data supportive of our
findings. In one (16), hepatic glucose output rose significantly early during the epinephrine infusion [when it would be expected to have its greatest effect (35)], despite the very low exercise capacity of the subjects
(
O2 max 19 ml · kg
1 · min
1).
In the other (15), as previously mentioned, epinephrine accounted for a
significant proportion of the response, despite a somewhat lower
exercise intensity and much lower epinephrine levels than in our
subjects exercised at 87%
O2 max
(24).
Our finding of increased glucose disposal during the epinephrine infusion is novel, as it is generally accepted that glucose uptake should be inhibited. Whereas in human studies of epinephrine infusion at rest (5, 30-32) Rd changed little, and MCR declined 20-40%, results during exercise have varied.
One study (16) showed declines in both Rd and MCR in
adrenalectomized subjects (five female, one male) exercising at high relative (68 and 84%
O2 max) but very low
absolute exercise intensities
(
O2 of 13.1 and 16.3 ml · kg
1 · min
1)
with and without epinephrine infusion. Another (15) showed no
statistically significant change (though an upward trend) in Rd and MCR during infusion of epinephrine to plasma levels
of ~2 nM in subjects while exercising at 40%
O2 max. In our study, Rd rapidly rose an additional 57% and MCR an additional
44% from their values at 50%
O2 max (increments of
99 and 81% above resting values). Whereas the differences between our
results and those of Ref. 15 could be due to epinephrine dose, those
with Ref. 16 could relate to the very low absolute exercise intensity or to a training-dependent or sex-specific nature of the
epinephrine-Rd effect during exercise. It could be viewed
as "advantageous" for epinephrine to have different effects on
glucose disposal between intense exercise and severe
nonexercise-related metabolic stresses. In vitro data could
explain our observation, at least in part. Insulin and potassium
depolarization (mimicking the initial phase of excitation-contraction
coupling) increases glucose uptake via distinct pathways of GLUT-4
glucose transporter recruitment (28). Epinephrine has been shown to
translocate GLUT-4 while increasing glucose transport in the absence of
insulin but inhibiting glucose transport in the presence of insulin
(13). It has also been shown that epinephrine inhibits glucose
phosphorylation, which may become the rate-limiting step in glucose
utilization under certain circumstances, much less during muscle
contraction than during insulin stimulation (1). Another possible
explanation for increased Rd might be that, if adipose
tissue blood flow were to have decreased as in IE, free fatty acid
release would decrease, thereby favoring oxidation of glucose. The
latter did occur during the epinephrine infusion according to the RER
response. Finally, the possibility of a yet-undefined signaling
mechanism between liver and muscle that causes increased glucose uptake
when Ra increases cannot be excluded, nor can an effect of
epinephrine on muscular contractions (although
O2 did not change during epinephrine infusion).
In summary, this study has shown that the Ra, Rd, glycemic, lactate, and RER responses to epinephrine infusion during moderate-intensity exercise can reproduce the pattern of those of intense exercise. This adds support to the view that the pronounced rise of plasma catecholamines during IE could be the primary drive behind the marked stimulation of hepatic glucose output. Our results suggest that epinephrine alone cannot account for the full increment of Ra in IE. In addition, we have shown that the effect of epinephrine on glucose uptake and clearance during exercise appears to differ from its effect at rest, becoming stimulatory rather than inhibitory. This would enhance the body's ability to shift to higher levels of muscular carbohydrate use during intense exercise, while still being consistent with epinephrine contributing to hyperglycemia during non-exercise-related stresses.
![]() |
ACKNOWLEDGEMENTS |
---|
The authors gratefully acknowledge the contributions of the following, whose roles were essential to this research: Mary Shingler of the Royal Victoria Hospital Clinical Investigation Unit, Madeleine Giroux, Marie Lamarche, and Ginette Sabourin for technical assistance in Montreal, Marla Smith for technical assistance in Ann Arbor, and Josie Plescia and Janice Choma for secretarial assistance.
![]() |
FOOTNOTES |
---|
This work was supported by Grants MT9581 (to E. B. Marliss) and MT2197 (to M. Vranic) from the Medical Research Council of Canada. The laboratory of J. B. Halter is supported by the Medical Research Service of the US Department of Veterans Affairs. N. Ah Mew, M. Arsenault and S. J. Nessim were summer research students in the Faculty of Medicine, McGill University.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: E. B. Marliss, McGill Nutrition and Food Science Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, QC, Canada H3A 1A1 (E-mail: Errol.Marliss{at}muhc.mcgill.ca).
Received 23 August 1999; accepted in final form 13 December 1999.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Aslesen, R,
and
Jensen J.
Effects of epinephrine on glucose metabolism in contracting rat skeletal muscles.
Am J Physiol Endocrinol Metab
275:
E448-E456,
1998
2.
Berger, CM,
Sharis PJ,
Bracy DP,
Lacy DB,
and
Wasserman DH.
Sensitivity of exercise-induced increase in hepatic glucose production to glucose supply and demand.
Am J Physiol Endocrinol Metab
267:
E411-E421,
1994
3.
Bradley, DC,
Steil GM,
and
Bergman RN.
OOPSEG: a data smoothing program for quantitation and isolation of random measurement error.
Comput Methods Programs Biomed
46:
67-77,
1995[ISI][Medline].
4.
Calles, J,
Cunningham JJ,
Nelson L,
Brown N,
Nadel E,
Sherwin RS,
and
Felig P.
Glucose turnover during recovery from intensive exercise.
Diabetes
32:
734-738,
1983[ISI][Medline].
5.
Clutter, WE,
Bier DM,
Shah SD,
and
Cryer PE.
Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man.
J Clin Invest
66:
94-101,
1980[ISI][Medline].
6.
Coggan, AR,
Raguso CA,
Gastaldelli A,
Williams BD,
and
Wolfe RR.
Regulation of glucose production during exercise at 80% of O2 peak in untrained humans.
Am J Physiol Endocrinol Metab
273:
E348-E354,
1997
7.
Coker, RH,
Krishna MG,
Lacy DB,
Bracy DP,
and
Wasserman DH.
Role of hepatic - and
-adrenergic receptor stimulation on hepatic glucose production during heavy exercise.
Am J Physiol Endocrinol Metab
273:
E831-E838,
1997
8.
Connolly, CC,
Steiner KE,
Stevenson RW,
Neal DW,
Williams PE,
Alberti KG,
and
Cherrington AD.
Regulation of glucose metabolism by norepinephrine in conscious dogs.
Am J Physiol Endocrinol Metab
261:
E764-E772,
1991
9.
Evans, MI,
Halter JB,
and
Porte D.
Comparison of double- and single-isotope enzymatic derivative methods for measuring catecholamines in plasma.
Clin Chem
28:
764-770,
1978.
10.
Febbraio, MA,
Lambert DL,
Starkie RL,
and
Proietto J.
Effect of epinephrine on muscle glycogenolysis during exercise in trained men.
J Appl Physiol
84:
465-470,
1998
11.
Fisher, SJ,
Shi ZQ,
Lickley HLA,
Efendic S,
Vranic M,
and
Giacca A.
A moderate decline in specific activity does not lead to an underestimation of hepatic glucose production during a glucose clamp.
Metabolism
45:
587-593,
1996[ISI][Medline].
12.
Gray, DE,
Lickley HL,
and
Vranic M.
Physiologic effects of epinephrine on glucose turnover and plasma free fatty acid concentrations mediated independently of glucagon.
Diabetes
29:
600-608,
1980[ISI][Medline].
13.
Han, X-X,
and
Bonen A.
Epinephrine translocates GLUT-4 but inhibits insulin-stimulated glucose transport in rat muscle.
Am J Physiol Endocrinol Metab
274:
E700-E707,
1998
14.
Hirsch, IB,
Marker JC,
Smith LJ,
Spina RJ,
Parvin CA,
Holloszy JO,
and
Cryer PE.
Insulin and glucagon in prevention of hypoglycemia during exercise in humans.
Am J Physiol Endocrinol Metab
260:
E695-E704,
1991
15.
Howlett, K,
Febbraio M,
and
Hargreaves M.
Glucose production during strenuous exercise in humans: role of epinephrine.
Am J Physiol Endocrinol Metab
276:
E1130-E1135,
1999
16.
Howlett, K,
Galbo H,
Lorentsen J,
Bergeron R,
Zimmerman-Belsing T,
Bülow J,
Feldt-Rasmussen U,
and
Kjaer M.
Effect of adrenaline on glucose kinetics during exercise in adrenalectomised humans.
J Physiol (Lond)
519:
911-921,
1999
17.
Jenkins, AB,
Chisholm DJ,
James DE,
Ho KY,
and
Kraegen EW.
Exercise-induced hepatic glucose output is precisely sensitive to the rate of systemic glucose supply.
Metabolism
34:
431-436,
1985[ISI][Medline].
18.
Jenkins, AB,
Furler SM,
Chisholm DJ,
and
Kraegen EW.
Regulation of hepatic glucose output during exercise by circulating glucose and insulin in humans.
Am J Physiol Regulatory Integrative Comp Physiol
250:
R411-R417,
1986
19.
Kjaer, M,
Engfred K,
Fernandes A,
Secher NH,
and
Galbo H.
Regulation of hepatic glucose production during exercise in humans: role of sympathoadrenergic activity.
Am J Physiol Endocrinol Metab
265:
E275-E283,
1993
20.
Kjaer, M,
Farrell PA,
Christensen NJ,
and
Galbo H.
Increased epinephrine response and inaccurate glucoregulation in exercising athletes.
J Appl Physiol
61:
1693-1700,
1986
21.
Kjaer, M,
Keiding S,
Engfred K,
Rasmussen K,
Sonne B,
Kirkegård P,
and
Galbo H.
Glucose homeostasis during exercise in humans with a liver or kidney transplant.
Am J Physiol Endocrinol Metab
268:
E636-E644,
1995
22.
Kjaer, M,
Secher NH,
Bach FW,
Sheikh S,
and
Galbo H.
Hormonal and metabolic responses to exercise in humans: effect of sensory nervous blockade.
Am J Physiol Endocrinol Metab
257:
E95-E101,
1989
23.
Lindfeldt, J,
Balkan B,
van Dijk G,
Scheurink A,
Ahren B,
and
Steffens AB.
Influence of peri-arterial hepatic denervation on the glycemic response to exercise in rats.
J Auton Nerv Syst
44:
45-52,
1993[ISI][Medline].
24.
Manzon, A,
Fisher SJ,
Morais JA,
Lipscombe L,
Guimond MC,
Nessim SJ,
Sigal RJ,
Halter JB,
Vranic M,
and
Marliss EB.
Glucose infusion partially attenuates glucose production and increases uptake during intense exercise.
J Appl Physiol
85:
511-524,
1998
25.
Marliss, EB,
Ah Mew N,
Arsenault M,
Halter JB,
and
Vranic M.
Epinephrine (EPI) infusion during moderate exercise converts the glucoregulatory response to that of intense exercise (Abstract).
Diabetes
48, Suppl 1:
177,
1999.
26.
Marliss, EB,
Kreisman SH,
Manzon A,
Halter JB,
Vranic M,
and
Nessim SJ.
Gender differences in glucoregulatory responses to intense exercise.
J Appl Physiol
88:
457-466,
2000
27.
Marliss, EB,
Manzon A,
Nessim S,
Morais JA,
and
Fisher SJ.
Glucoregulatory responses to intense exercise performed in the postprandial state.
Am J Physiol Endocrinol Metab
278:
E786-E793,
2000
28.
Nagy, LE,
and
Bo Y.
Additive stimulation of glucose uptake and GLUT4 translocation to the plasma membrane after insulin and K+-depolarization in cultured H9cZ myotubes (Abstract).
Diabetes
46, Suppl1:
73,
1999.
29.
Radziuk, J,
Norwich KM,
and
Vranic M.
Experimental validation of measurements of glucose turnover in nonsteady state.
Am J Physiol Endocrinol Metab Gastrointest Physiol
234:
E84-E93,
1978
30.
Rizza, RA,
Cryer PE,
Haymond MW,
and
Gerich JE.
Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man.
J Clin Invest
65:
682-689,
1980[ISI][Medline].
31.
Rizza, RA,
Haymond M,
Cryer P,
and
Gerich J.
Differential effects of epinephrine on glucose production and disposal in man.
Am J Physiol Endocrinol Metab Gastrointest Physiol
237:
E356-E362,
1979
32.
Sacca, L,
Morrone G,
Cicala M,
Corso G,
and
Ungaro B.
Influence of epinephrine, norepinephrine, and isoproterenol on glucose homeostasis in normal man.
J Clin Endocrinol Metab
50:
680-684,
1980[ISI][Medline].
33.
Sacca, L,
Vigorito C,
Cicala M,
Corso G,
and
Sherwin RS.
Role of gluconeogenesis in epinephrine-stimulated hepatic glucose production in humans.
Am J Physiol Endocrinol Metab
245:
E294-E302,
1983
34.
Schricker, T,
Albuszies G,
Weidenbach H,
Beckh K,
Ensinger H,
Anhaupl T,
Radermacher P,
Vogt J,
Adler G,
and
Georgieff M.
Effects of epinephrine on glucose metabolism in patients with alcoholic cirrhosis.
Hepatology
24:
330-336,
1996[ISI][Medline].
35.
Sherwin, RS,
and
Sacca L.
Effect of epinephrine on glucose metabolism in humans: contribution of the liver.
Am J Physiol Endocrinol Metab
247:
E157-E165,
1984
36.
Shi, ZQ,
Wasserman DH,
and
Vranic M.
Metabolic implications of exercise and physical fitness in physiology and diabetes.
In: Ellenberg and Rifkin's Diabetes Mellitus: Theory and Practice (5th ed.), edited by Porte D,
and Sherwin R. E.. Norwalk, CT: Appleton-Lang, 1997, p. 653-687.
37.
Sigal, RJ,
Fisher S,
Halter JB,
Vranic M,
and
Marliss EB.
The roles of catecholamines in glucoregulation in intense exercise as defined by the islet cell clamp technique.
Diabetes
45:
148-156,
1996[Abstract].
38.
Sigal, RJ,
Fisher SJ,
Manzon A,
Morais JA,
Halter JB,
Vranic M,
and
Marliss EB.
Glucoregulation during and after intense exercise: effects of -adrenergic blockade.
Metabolism
49:
386-394,
2000[ISI][Medline].
39.
Sigal, RJ,
Purdon C,
Bilinski D,
Vranic M,
Halter JB,
and
Marliss EB.
Glucoregulation during and after intense exercise: effects of beta-blockade.
J Clin Endocrinol Metab
78:
359-366,
1994[Abstract].
40.
Stevenson, RW,
Steiner KE,
Connolly CC,
Fuchs H,
Alberti KGMM,
Williams PE,
and
Cherrington AD.
Dose-related effects of epinephrine on glucose production in conscious dogs.
Am J Physiol Endocrinol Metab
260:
E363-E370,
1991
41.
Vissing, J,
Sonne B,
and
Galbo H.
Regulation of hepatic glucose production in running rats studied by glucose infusion.
J Appl Physiol
65:
2552-2557,
1988
42.
Wasserman, DH.
Regulation of glucose fluxes during exercise in the postabsorptive state.
Annu Rev Physiol
57:
191-218,
1995[ISI][Medline].
43.
Wasserman, DH,
Spalding JA,
Lacy DB,
Colburn CA,
Goldstein RE,
and
Cherrington AD.
Glucagon is a primary controller of hepatic glycogenolysis and gluconeogenesis during muscular work.
Am J Physiol Endocrinol Metab
257:
E108-E117,
1989
44.
Weirsma, MM,
Vissing J,
Mikines KJ,
Steffens AB,
and
Galbo H.
Effect of liver denervation on glucose production during running in guinea pigs.
Am J Physiol Regulatory Integrative Comp Physiol
268:
R72-R77,
1995
45.
Weirsma, MM,
Vissing J,
Steffens AB,
and
Galbo H.
Effects of glucose infusion on hormone secretion and hepatic glucose production during heavy exercise.
Am J Physiol Regulatory Integrative Comp Physiol
265:
R1333-R1338,
1993